Essa Pharma Shares Drop 26% After Janssen Suspends Enrollment for Trials
October 31 2022 - 7:36AM
Dow Jones News
By Chris Wack
Essa Pharma Inc. shares were down 26% to $3.25 in premarket
trading after the company said that Janssen Research &
Development is suspending enrollment in the Phase 1 clinical study
of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate
plus prednisone in metastatic castration-resistant prostate cancer
patients as a result of operational recruitment challenges.
Before suspending enrollment, Janssen treated three mCRPC
patients with the combination of EPI-7386 and apalutamide or
abiraterone acetate plus prednisone for up to four months of
therapy, the company said.
In all three patients, the combination of both investigational
drug products was safe and well tolerated, and yielded sufficient
exposures of each investigational drug product, indicative of
pharmacological activity. Initial clinical activity was observed in
some patients, with two of the three patients achieving a
prostate-specific antigen reduction of 90% within 12 weeks, the
company said.
"We are encouraged by the favorable safety, pharmacokinetic, and
initial clinical activity in these patients as these data further
support the data generated in the EPI-7386 combination study with
enzalutamide that Essa is conducting," David Parkinson, chief
executive of Essa, said.
"We are in discussions with Janssen to supply abiraterone
acetate and apalutamide for an Essa-sponsored combination study and
expect to provide more details in the coming months."
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 31, 2022 08:21 ET (12:21 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
